Acalabrutinib study in Indian patients with chronic lymphocytic leukaemia & relapsed and refractory mantle cell lymphoma

Trial Identifier: D8220C00022
Sponsor: AstraZeneca
NCTID:: NCT04930536
Start Date: July 2021
Primary Completion Date: May 2023
Study Completion Date: May 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Telugu Translation
Assamese Translation
Bengali Translation
Punjabi Translation
Urdu Translation
Kannada Translation
Marathi Translation
Tamil Translation
Gujarati Translation
Hindi Translation
Malayalam Translation

Trial Locations

Country Location
IN Ahmedabad, IN, 380009
IN Bangalore, IN, 560017
IN Bangalore, IN, 560064
IN Bengaluru, IN, 560099
IN Chandigarh, IN, 160012
IN Gurugram, IN, 122001
IN Guwahati, IN, 781032
IN Hyderabad, IN, 500033
IN Hyderabad, IN, 500019
IN Kochi, IN, 682041
IN Kolkata, IN, 700160
IN Ludhiana, IN, 141 008
IN Mumbai, IN, 400012
IN Mumbai, IN, 400010
IN New Delhi, IN, 110 085